A potential role of direct inhibitors of IL-17 in lupus nephritis has been suggested, since Th17 cells are involved in SLE pathogenesis as combination therapy, and after some successful case reports described in the literature, a phase III RCT to evaluate secukinumab in patients with active lupus nephritis has been conducted (CTI: NCT04181762). The gene discussed is IL17A; the disease is systemic lupus erythematosus.